International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 243-245 www.ijprajournal.com ISSN: 2456-4494

The Expanding Role of Biosimilar in Autoimmune Diseases

Imtiyaz Ahmad*, [2]Dr. Pushpa Yadav, [3]Mr. Shailendra Kumar Dwivedi
[1]*Assistant professor Nova College of Pharmacy, Lucknow, U.P. India*
[2]*Associate professor Nova College of Pharmacy, Lucknow, U.P. India*
[3]*Assistant professor Nova College of Pharmacy, Lucknow, U.P. India*
Corresponding author- Mr. Imtiyaz Ahmad

Date of Submission: 10-07-2025 Date of Acceptance: 20-07-2025

ABSTRACT
The advent of biosimilar has significantly transformed the therapeutic landscape of autoimmune diseases. These agents, developed to be highly similar to approved biologic reference products, offer comparable efficacy and safety at reduced costs. Their introduction has facilitated broader access to biologic treatments, improved healthcare sustainability, and stimulated competition in the pharmaceutical industry. This review explores the development, regulatory frameworks, clinical applications, safety profiles, challenges, and future directions of biosimilar in the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

I. INTRODUCTION

Autoimmune diseases are chronic conditions characterized by immune system dysregulation, leading to inflammation and tissue damage. Biologic therapies, especially monoclonal antibodies targeting tumour necrosis factor-alpha (TNF-α) and interleukins, have revolutionized treatment but remain cost-prohibitive for many patients. Biosimilar—biologic products with high similarity to already approved biologics—have emerged as a cost-effective alternative, aiming to enhance access and reduce healthcare burdens.

II. UNDERSTANDING BIOSIMILAR

2.1 Definition

Biosimilar are not generic drugs but are developed through complex biotechnological processes using living organisms. Regulatory agencies such as the FDA and EMA define biosimilar as products that have no clinically meaningful differences in terms of safety, purity, and potency compared to the reference product.

2.2 Characteristics of Biosimilar

- **High Similarity to Reference Product**

Biosimilar are almost identical to the reference product in terms of structure, function, and clinical efficacy.
Minor differences in clinically inactive components (like stabilizers or preservatives) are allowed.

- **No Clinically Meaningful Differences**

Clinical studies must demonstrate that there are **no meaningful differences** in safety or effectiveness compared to the original biologic.

- **Complex Structure**
- biosimilar, like all biologics, are **large, complex molecules** made from living cells. This makes them more complicated than small-molecule generics.
-
- **Manufacturing Variability**

Because they are derived from living systems, slight variability is expected even within batches of the same product. However, these variations are strictly controlled.

- **Rigorous Regulatory Evaluation**

Approval involves **analytical studies**, **animal studies** (if necessary), and **clinical trials** to confirm biosimilarity.
Agencies like the **FDA**, **EMA**, and **WHO** have strict guidelines for approval.

- **Interchangeability (Optional and Regulated)**

In some jurisdictions (like the U.S.), a biosimilar can be designated as **interchangeable**, meaning it can be substituted for the reference product without the prescribing physician's input.
Interchangeability requires additional evidence, especially regarding safety in switching.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 243-245 www.ijprajournal.com ISSN: 2456-4494

- **Cost-Effective Alternative**

While not as cheap as generics, biosimilar typically cost **15–30% less** than the reference biologic, improving access to treatment.

2.3 Development and Approval

The development of biosimilar involves analytical characterization, preclinical studies, and clinical trials to demonstrate biosimilarity. Approval pathways are abbreviated compared to originator biologics but still require rigorous evidence. Some biosimilar are also granted interchangeability status, allowing for substitution at the pharmacy level in certain jurisdictions. Following steps involved for the approval of biosimilar.

2.3.1 Analytical and Structural Characterization

Goal**:** Demonstrate molecular and structural similarity to the reference biologic.
Methods: Advanced techniques (e.g., mass spectrometry, chromatography, X-ray crystallography) to compare:

- Amino acid sequence
- Post-translational modifications (e.g., glycosylation)
- Higher-order structures
- Impurities and aggregates

2.3.2 Nonclinical Studies (Preclinical)

- **In vitro** (e.g., receptor binding, bioactivity)
- **In vivo** (animal studies) to assess:

Toxicity
Pharmacokinetics (PK)
Immunogenicity (potential immune responses)

2.3.3 Clinical Studies

- Phase I – Pharmacokinetics/Pharmacodynamics (PK/PD)

Head-to-head comparison with reference product
Conducted in healthy volunteers or patients

- Phase III – Confirmatory Clinical Trials

Assess **efficacy**, **safety**, and **immunogenicity** in one or more sensitive indications
Goal is to demonstrate **no clinically meaningful differences** with the reference biologic

2.3.4 Regulatory Submission

Each regulatory authority has its own pathway. For example:

- **FDA (U.S.):** 351(k) Biologics License Application (BLA)
- **EMA (EU):** Centralized procedure via European Medicines Agency
- **WHO:** Guidelines for global biosimilar approval

2.3.5 The submission includes:

- Analytical data
- Nonclinical results
- Clinical trial data
- Manufacturing information
- Risk management plans

2.3.6 Approval and Post-Market Surveillance

After approval:

- Biosimilar is allowed to market for **approved indications** (may include extrapolated indications not directly studied)
- Subject to **pharmacovigilance**: monitoring for rare or long-term adverse effects
- Interchangeability status (especially in the U.S.) may require additional data

III. CLINICAL APPLICATIONS IN AUTOIMMUNE DISEASES

3.1 Rheumatoid Arthritis and Other Arthritis's

TNF inhibitors like infliximab, adalimumab, and etanercept are commonly used in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Biosimilar such as CT-P13 (Inflectra/Remsima) and ABP 501 (Amjevita) have demonstrated comparable efficacy and safety in large randomized trials and real-world studies.

3.2 Inflammatory Bowel Disease (IBD)

Infliximab and adalimumabbiosimilar are widely used in Crohn's disease and ulcerative colitis. Studies like the NOR-SWITCH trial showed that switching to biosimilar did not compromise efficacy or safety, supporting their integration into IBD treatment guidelines.

3.3 Psoriasis and Dermatologic Conditions

Biosimilar of etanercept and adalimumab are increasingly used in moderate-to-severe plaque psoriasis. Clinical trials confirm their comparable efficacy in skin clearance and quality of life improvement.

IV. SAFETY AND IMMUNOGENICITY

Immunogenicity is a critical consideration with biologics. Biosimilar undergo extensive testing to ensure they do not provoke higher immune responses than originators. Data from

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 243-245 www.ijprajournal.com ISSN: 2456-4494

switching studies and pharmacovigilance programs indicate that adverse event profiles remain consistent after switching to biosimilar.

V. ECONOMIC AND POLICY IMPACT

5.1 Cost Savings

Biosimilar can cost 15–50% less than reference products. Their use has already led to significant savings in European healthcare systems, and similar trends are emerging globally.

5.2 Access and Equity

Lower prices improve access in low- and middle-income countries, helping reduce disparities in care for patients with autoimmune diseases. Expanded access may also reduce disease burden and long-term disability.

5.3 Healthcare System Dynamics

Competition from biosimilar may drive down prices of originators and foster innovation. Payer and provider incentives are evolving to encourage biosimilar uptake through formulary positioning, step therapy, and shared savings programs.

VI. CHALLENGES AND BARRIERS

Despite the benefits, adoption is uneven due to:

- Physician and patient hesitation
- Misinformation or lack of awareness
- Complex patent landscapes and legal hurdles
- Variability in regulatory and substitution policies across countries
- Educational efforts and transparent communication are vital to overcoming these obstacles.

VII. FUTURE DIRECTIONS

The biosimilar market is poised to expand with the expiration of patents on key biologics, including interleukin inhibitors (e.g., ustekinumab). Future advancements include:

- Development of subcutaneous biosimilar
- Wider interchangeability designations
- Digital health integration for real-time monitoring
- Global harmonization of biosimilar regulations

VIII. CONCLUSION

Biosimilar have emerged as transformative agents in the management of autoimmune diseases, offering comparable safety, efficacy, and quality to originator biologics at significantly lower costs. Their introduction has expanded patient access to life-altering therapies, alleviated financial burdens on healthcare systems, and promoted market competition. Robust regulatory frameworks ensure their scientific rigor, while real-world evidence supports their effectiveness across conditions such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Despite challenges like physician hesitation, regulatory variability, and misinformation, ongoing education and policy reforms are gradually improving acceptance. As the biosimilar market continues to grow—with new molecules, broader interchangeability, and digital health integration—biosimilar are positioned to play an increasingly central role in ensuring equitable and sustainable treatment for autoimmune diseases worldwide.

REFERENCES

(Note: Add actual citations here from peer-reviewed journals, regulatory agencies, and clinical trials. Examples below as placeholders.)

[1]. Cohen HP, Blauvelt A, Rifkin RM, et al. Biosimilar: Implications for clinical practice. N Engl J Med. 2021;384(2):136–144.

[2]. Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 in autoimmune diseases: NOR-SWITCH trial. Lancet. 2017;389(10086):2304–2316.

[3]. FDA. Biosimilar Product Information. https://www.fda.gov

[4]. EMA. Biosimilars in the EU: Information guide for healthcare professionals. https://www.ema.europa.eu

[5]. **Konkolewicz D, et al.** "Switching from originator infliximab to biosimilar CT-P13: randomized, double-blind NOR-SWITCH trial." The Lancet, 2017.

[6]. **Stajszczyk M, et al.** "Economic evaluation of biosimilars in rheumatoid arthritis: outcomes from Poland and six Eastern European countries." Foster Healthcare Systems Sustainability, 2021.

[7]. **Choe JY, et al.** "Treatment journey in rheumatoid arthritis with biosimilars: from better access to disease control through cost savings and nocebo effect prevention." Rheumatology Advances in Practice, 2021.